NeuroKaire

NeuroKaireNeuroKaire
NeuroKaire

NeuroKaire

Personalized medical testing tool to optimize drug therapy for depression.

Website
2017Active36
Rate
Advertise here

About

NeuroKaire transforms depression medication selection by understanding how each patient's unique brain and body responds to medication, moving beyond trial-and-error. Their service helps evaluate how different antidepressants are likely to interact with a person's brain biology before treatment starts, guiding treatment choices with greater confidence. NeuroKaire serves both patients and providers.

Technology stack

detected 2026-06-28
EmailGoogle Workspace
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does NeuroKaire do?

NeuroKaire transforms depression medication selection by understanding how each patient's unique brain and body responds to medication, moving beyond trial-and-error. Their service helps evaluate how different antidepressants are likely to interact with a person's brain biology before treatment starts, guiding treatment choices with greater confidence. NeuroKaire serves both patients and providers. (formerly Genetika+.)

How much funding has NeuroKaire raised?

NeuroKaire has raised a total of $27M in funding. The most recent round on record is Grant.

Where is NeuroKaire headquartered?

NeuroKaire is headquartered in Tel Aviv, Israel.

When was NeuroKaire founded?

NeuroKaire was founded in 2017.

What industry does NeuroKaire operate in?

NeuroKaire operates in Neuroscience, Biotech, Mental Health, Drug Therapy, Depression, Personalized Treatment.

How many employees does NeuroKaire have?

NeuroKaire has approximately 36 people on record.